We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Nurtec

News List

FDA Approves Biohaven's NURTEC® ODT: First and Only Migraine Medication for both Acute and Preventive Treatment americanpharmaceuticalreview
June 02, 2021
Biohaven Pharmaceutical Holding Company announced that the U.S. FDA has approved NURTEC® ODT (rimegepant 75 mg) for the preventive treatment of migraine.
Biohaven’s Nurtec fails to obtain FDA approval for ALS pharmaceutical-technology
July 23, 2019
Biohaven Pharmaceutical has failed to receive the US Food and Drug Administration (FDA) approval for Nurtec (riluzole).
Complete response letter given to ALS treatment for API concern europeanpharmaceuticalreview
July 23, 2019
The FDA has handed a CRL to Biohaven for its ALS treatment awaiting approval due to concerns regarding the medication’s API.